Healthcare
Sana Biotechnology, Inc.(SANA)
Live Price
Offline$3.15
+3.62% today
1Y Change
+21.15%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $910.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +17.2%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sana Biotechnology, Inc. (SANA) is a Healthcare stock with a market cap of $910.00M and listed on NASDAQ. The stock last traded around $3.15 and up 21.2% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +17.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +17.2%, free cash flow +43.6% with operating margin 0.0% and ROIC -70.9%. Stock Foundry combines SANA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +17.2%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -8.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -2.2% | +0.3% | -14.6% |
2026 Mar 3, 2026 | -23.1% | -2.8% | -16.3% | -26.7% |
2025 Nov 6, 2025 | +16.7% | +1.0% | -9.6% | +26.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SANA
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SANA Max Drawdown
-54.73%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SANA and SPY.
Company Overview
Sana Biotechnology, Inc.
NASDAQ Global Select
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
- Leadership
- Steven D. Harr
- IPO Date
- Feb 4, 2021
- Employees
- 194
- Street Address
- 188 East Blaine Street
- Mailing
- Seattle, WA, 98102
- Region
- Seattle, WA, US
- Reporting Currency
- USD
- Investor Line
- 206 701 7914
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 5.4
Growth
- Revenue
- 0.0%
- EPS
- +17.2%
- Free Cash Flow
- +43.6%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -142.0%
- ROIC
- -70.9%
Balance Sheet
- Debt/Equity
- 0.49
- Current Ratio
- 1.89
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.